ClinicalTrials.gg
Enrolling by invitationNCT05349409Updated Jun 30, 2022

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

A Phase 2 interventional study of SHR-A1811 and Fluzoparib Capsule in Advanced Solid Tumors, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Enrolling by invitation at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-30.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
212
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is being conducted to evaluate safety, tolerability and preliminary efficacy of SHR-A1811 for Injection in combination with Fluzoparib Capsule for HER2-expressing advanced solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination therapy for HER2-expressing advanced malignant tumors of patients.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥18 years at the time of signing the ICF.
  2. At least one that meets 1.1 criteria in case of solid tumors.
  3. An (ECOG) performance status (PS) score of 0 or 1.
  4. ≥12 weeks.
  5. Adequate organ functions as defined.
  6. Swallow the drug pills normally.

Exclusion criteria

Exclusion Criteria:

  1. patients with active meningeal , or without surgical treatment or radiotherapy.
  2. Cancerous ascites and pleural effusion with clinical symptoms, which need puncture and drainage.
  3. Prior (other than current malignant tumor) within 5 years before the first dose of study treatment.
  4. History of diseases.
  5. Not well controllable and serve cardiovascular disease.
  6. Prior lung disease with clinical significance.
  7. Occurrence of ≥ grade 2 of bleeding event within 4 weeks before the first dose, or currently receiving the anticoagulation.
  8. Active and ; or serve infection with medication control.
  9. The grade of toxicity from the prior anti-cancer therapy not decrease to ≤ 1.
  10. Occurrence of intestinal obstruction and gastrointestinal perforation within 3 months before the first dose.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    Treatment group

    SHR-A1811, Fluzoparib

    Drug: SHR-A1811 · Drug: Fluzoparib Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limited Toxicity

    Dose Limited Toxicity of SHR-A1811 for Injection in combination with Fluzoparib Capsule in Dose Exploration Period

    Time frame: first dose of study medication up to 21 days

  2. Recommended phase II dose

    The Recommended phase II dose of SHR-A1811 for Injection in combination with Fluzoparib Capsule in Dose Exploration Period

    Time frame: first dose of study medication up to 21 days

  3. ORR

    Objective Response Rate, Efficacy endpoints of SHR-A1811 for Injection in combination with Fluzoparib Capsule in HER2-Expressing Advanced Solid Tumors of Patients in indication expansion period

    Time frame: from the date of the first dose to the date of disease progression evaluated based on RECIST v1.1 criteria, or initiation of other anti-tumor treatment, whichever occurs first, up to 6 months

Secondary outcomes

  1. DoR

    Duration of response, Efficacy endpoints of SHR-A1811 for Injection in combination with Fluzoparib Capsule in HER2-Expressing Advanced Solid Tumors of Patients

    Time frame: from the date of the firstly documented tumor response (evaluated based on RECIST v1.1 criteria) to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, up to 6 months

  2. DCR

    Disease control rate, Efficacy endpoints of SHR-A1811 for Injection in combination with Fluzoparib Capsule in HER2-Expressing Advanced Solid Tumors of Patients

    Time frame: from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, up to 6 months

  3. TTR

    Time to Recovery, Efficacy endpoints of SHR-A1811 for Injection in combination with Fluzoparib Capsule in HER2-Expressing Advanced Solid Tumors of Patients

    Time frame: from the date of the first dose to the date of treatment termination, up to 6 months

  4. PFS

    Progression-free survival, Efficacy endpoints of SHR-A1811 for Injection in combination with Fluzoparib Capsule in HER2-Expressing Advanced Solid Tumors of Patients

    Time frame: from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, up to 6 months

  5. OS

    Overall survival, Efficacy endpoints of SHR-A1811 for Injection in combination with Fluzoparib Capsule in HER2-Expressing Advanced Solid Tumors of Patients

    Time frame: from the date of the first dose to the date of death for any reason, up to 100 months

  6. 12 months' survival rate

    Efficacy endpoints of SHR-A1811 for Injection in combination with Fluzoparib Capsule in HER2-Expressing Advanced Solid Tumors of Patients

    Time frame: from the date of the first dose up to 12 months

  7. Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)

    Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: from signature completion of ICF to 30 days after the last dose or to the beginning of the new anti-cancer therapy, up to 6 months

  8. The occurrence rate of dose titration due to AE related with study medication

    The occurrence rate of dose interruption, dose decrease and dose termination because of study drug related toxicity during the study

    Time frame: from signature completion of ICF to 30 days after the last dose or to the beginning of the new anti-cancer therapy, up to 6 months

  9. Cmin

    PK concentration of Fluzoparib Capsule

    Time frame: 10 min before first dose of Fluzoparib Capsule in C1D8 to 10 min before first dose of Fluzoparib Capsule in C8D1

  10. C3h

    PK concentration of Fluzoparib Capsule

    Time frame: 3 hour after first dose of Fluzoparib Capsule in C2D1

  11. AUC0-t

    PK parameters of SHR-A1811 for Injection

    Time frame: the date of first dose to 30 days after last dose

  12. Cmin

    PK parameters of SHR-A1811 for Injection

    Time frame: the date of first dose to 30 days after last dose

  13. Cmax

    PK parameters of SHR-A1811 for Injection

    Time frame: the date of first dose to 30 days after last dose

  14. ADA

    Anti-drug antibody, Immunogenicity of SHR-A1811 for Injection

    Time frame: the date of first dose up to 90 days after last dose

  15. NAb

    Neutralizing Antibody, Immunogenicity of SHR-A1811 for Injection

    Time frame: the date of first dose up to 90 days after last dose

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Nov 2024, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2022
First posted
Apr 27, 2022
StartActual
Jun 9, 2022
Primary completionEst.
Nov 30, 2024
CompletionEst.
May 31, 2025
Last update
Jun 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05349409
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Jun 9, 2022
Primary completion
Nov 30, 2024 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Jun 30, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab rezetecan · Fluzoparib

Start the discussion